Sheila Duncan

1.3k total citations
11 papers, 333 citations indexed

About

Sheila Duncan is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Pharmacology. According to data from OpenAlex, Sheila Duncan has authored 11 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Epidemiology and 4 papers in Pharmacology. Recurrent topics in Sheila Duncan's work include Pneumonia and Respiratory Infections (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). Sheila Duncan is often cited by papers focused on Pneumonia and Respiratory Infections (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Pneumocystis jirovecii pneumonia detection and treatment (3 papers). Sheila Duncan collaborates with scholars based in United States. Sheila Duncan's co-authors include John E. Conte, Jeffrey A. Golden, E. Zurlinden, E T Lin, Elisabeth Zurlinden, Juliana Kipps, Mari McQuitty, Adi Diab, Han Liang and Jian Wang and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and Annals of Oncology.

In The Last Decade

Sheila Duncan

9 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheila Duncan United States 5 209 177 99 82 68 11 333
E. Zurlinden United States 8 231 1.1× 172 1.0× 105 1.1× 76 0.9× 58 0.9× 9 408
Juliana Kipps United States 8 250 1.2× 223 1.3× 293 3.0× 96 1.2× 40 0.6× 10 477
Kalpana B. Patel United States 9 191 0.9× 198 1.1× 85 0.9× 117 1.4× 37 0.5× 12 334
K. Louchahi France 12 144 0.7× 150 0.8× 36 0.4× 130 1.6× 102 1.5× 23 394
Jill Butterfield United States 13 163 0.8× 262 1.5× 156 1.6× 120 1.5× 28 0.4× 14 432
Lionell Mandell Canada 7 114 0.5× 233 1.3× 60 0.6× 92 1.1× 19 0.3× 8 406
Femke de Velde Netherlands 8 134 0.6× 186 1.1× 61 0.6× 65 0.8× 16 0.2× 10 314
Marie-France Kerguéris France 8 99 0.5× 135 0.8× 121 1.2× 65 0.8× 54 0.8× 12 329
J Bauchet France 13 142 0.7× 174 1.0× 74 0.7× 72 0.9× 22 0.3× 24 388
Jufang Wu China 14 153 0.7× 241 1.4× 155 1.6× 163 2.0× 18 0.3× 39 466

Countries citing papers authored by Sheila Duncan

Since Specialization
Citations

This map shows the geographic impact of Sheila Duncan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheila Duncan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheila Duncan more than expected).

Fields of papers citing papers by Sheila Duncan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheila Duncan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheila Duncan. The network helps show where Sheila Duncan may publish in the future.

Co-authorship network of co-authors of Sheila Duncan

This figure shows the co-authorship network connecting the top 25 collaborators of Sheila Duncan. A scholar is included among the top collaborators of Sheila Duncan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheila Duncan. Sheila Duncan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Jiang, Yan, Erma Levy, Sheila Duncan, et al.. (2023). The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 41(16_suppl). TPS9609–TPS9609. 2 indexed citations
3.
Keung, Emily Z., Nadim J. Ajami, Sheila Duncan, et al.. (2021). 191P Fecal microbiome in soft-tissue sarcoma (STS) patients treated with neoadjuvant immune checkpoint blockade (ICB). Annals of Oncology. 32. S1464–S1464. 1 indexed citations
4.
5.
Glitza, Isabella C., Michelle Rohlfs, Jessie Richard, et al.. (2018). A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). Annals of Oncology. 29. viii464–viii464. 4 indexed citations
6.
Conte, John E., Jeffrey A. Golden, Mari McQuitty, et al.. (2002). Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid. Antimicrobial Agents and Chemotherapy. 46(9). 3112–3112. 2 indexed citations
7.
Conte, John E., Jeffrey A. Golden, Mari McQuitty, et al.. (2002). Effects of Gender, AIDS, and Acetylator Status on Intrapulmonary Concentrations of Isoniazid. Antimicrobial Agents and Chemotherapy. 46(8). 2358–2364. 55 indexed citations
8.
Conte, John E., et al.. (1999). Intrapulmonary Concentrations of Pyrazinamide. Antimicrobial Agents and Chemotherapy. 43(6). 1329–1333. 45 indexed citations
9.
Conte, John E., et al.. (1999). Effect of Gender and Race on the Pharmacokinetics of Pentamidine in HIV-Infected Patients. Clinical Drug Investigation. 17(4). 293–299. 1 indexed citations
10.
Conte, John E., et al.. (1996). Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrobial Agents and Chemotherapy. 40(7). 1617–1622. 129 indexed citations
11.
Conte, John E., et al.. (1995). Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrobial Agents and Chemotherapy. 39(2). 334–338. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Zurlinden Breakdown of academic impact, for papers by Juliana Kipps Breakdown of academic impact, for papers by Kalpana B. Patel Breakdown of academic impact, for papers by K. Louchahi Breakdown of academic impact, for papers by Jill Butterfield Breakdown of academic impact, for papers by Lionell Mandell Breakdown of academic impact, for papers by Femke de Velde Breakdown of academic impact, for papers by Marie-France Kerguéris Breakdown of academic impact, for papers by J Bauchet Breakdown of academic impact, for papers by Jufang Wu
Rankless by CCL
2026